
LeonaBio Inc (LONA) Stock Forecast & Price Target
LeonaBio Inc (LONA) Analyst Ratings
Bulls say
LeonaBio is making significant progress in their pipeline development, with a focus on their lead drug candidates lasofoxifene and ATH-1105. Their rational development strategy supports the potential for lasofoxifene to become a leading treatment in the 2L ER+/HER2- metastatic breast cancer market and address the high unmet need for treatment-resistant breast cancer and ALS. With a well-funded financial position and a strong focus on commercial readiness, LeonaBio is strategically positioned for success in the biopharmaceutical industry.
Bears say
LeonaBio is a clinical-stage biopharmaceutical company with potential in its lead drug candidates lasofoxifene and ATH-1105, which have shown promising results in addressing high unmet medical needs in metastatic breast cancer and ALS, respectively. However, despite positive Phase 2 data for lasofoxifene and a strong pipeline of small-molecule candidates, the company faces significant risks in its early stages of development and will likely need to raise additional capital to support its operations. Therefore, from a financial standpoint, LeonaBio's negative outlook is driven by its lack of current revenue, high R&D expenses, and potential future financing needs.
This aggregate rating is based on analysts' research of LeonaBio Inc and is not a guaranteed prediction by Public.com or investment advice.
LeonaBio Inc (LONA) Analyst Forecast & Price Prediction
Start investing in LeonaBio Inc (LONA)
Order type
Buy in
Order amount
Est. shares
0 shares